Tag: Bury

Latest articles

image of pharmacy shelves full of medicines to show New community pharmacy quality standard highlights prevention role

New community pharmacy quality standard highlights prevention role

A new community pharmacy quality standard published by NICE says that the teams have the potential to play a greater role in health promotion...
image of tablet, magnifying glass, pad, pen and cogs with graphs and flow charts to show NICE wants more data on histology independent cancer treatments

NICE wants more data on histology independent cancer treatments

The National Institute for Health and Care Excellence (NICE) is encouraging further data collection on ‘game changing’ histology independent cancer treatments. This comes as...
White contract and black pen on blue background to show NICE approves Pfizer's Ibrance in new combination for certain breast cancers

NICE approves Pfizer’s Ibrance in new combination for certain breast cancers

Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following Pfizer's...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
ABPI responds to Government's announcement of details for supporting pharmaceutical companies’ investments in developing drugs to tackle AMR infections

Novartis releases new data on Cosentyx ® for psoriatic arthritis

Novartis releases new data on Cosentyx ® (secukinumab) from two trials of psoriatic arthritis (PsA) patients.   PsA is a complex disease with multiple manifestations driving...

Market Access in practice: do you have a strategy?

This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...
Bayer's Vitrakvi ® (larotrectinib) receives first tumour-agnostic licence in EU

Bayer’s Vitrakvi®▼ (larotrectinib) receives first tumour-agnostic licence in EU

Bayer has announced that the European Commission has granted conditional marketing authorisation in the European Union (EU) for the targeted oncology treatment Vitrakvi® (larotrectinib)....
moving up the career ladder: Making a career move in pharma

Making a career move in pharma

If you feel that you have gone as far as you can in your current role, it could be time to make a career...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription